clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

References related to abnormalities published in J. Antimicrob. Chemother.

PMID	Journal	Published Date	Author	Title
10552979	J. Antimicrob. Chemother.	1999	Adamsson I et al.	Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients.
10552982	J. Antimicrob. Chemother.	1999	Cirioni O et al.	In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii.
10350380	J. Antimicrob. Chemother.	1999	Debets-Ossenkopp YJ et al.	Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands.
11679574	J. Antimicrob. Chemother.	2001	Guyot A and Barrett SP	What is an appropriate control group to identify risk factors for Clostridium difficile-associated diarrhoea?
11481305	J. Antimicrob. Chemother.	2001	López-Brea M et al.	A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children.
11864956	J. Antimicrob. Chemother.	2002	Fujimura S et al.	In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults.
11909833	J. Antimicrob. Chemother.	2002	McNulty C et al.	Helicobacter pylori susceptibility testing by disc diffusion.
11909844	J. Antimicrob. Chemother.	2002	Thiermann S et al.	Comparison of phenotypic and genotypic methods for the detection of clarithromycin resistance in Mycobacterium avium.
11815577	J. Antimicrob. Chemother.	2002	Portier H et al.	Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: a multi-centre, open-label, randomized study.
11266421	J. Antimicrob. Chemother.	2001	Kim JJ et al.	Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea.
12003967	J. Antimicrob. Chemother.	2002	Kikuchi T et al.	Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors.
12003986	J. Antimicrob. Chemother.	2002	Yanagihara K et al.	Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model.
12096020	J. Antimicrob. Chemother.	2002	Koga T et al.	Effect of plaunotol in combination with clarithromycin or amoxicillin on Helicobacter pylori in vitro and in vivo.
12039897	J. Antimicrob. Chemother.	2002	Samra Z et al.	Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime.
12356809	J. Antimicrob. Chemother.	2002	Zapater P et al.	A prospective study of the clarithromycin-digoxin interaction in elderly patients.
12407126	J. Antimicrob. Chemother.	2002	Mainz D et al.	Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration.
12562704	J. Antimicrob. Chemother.	2003	Loughlin MF et al.	Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice.
12615872	J. Antimicrob. Chemother.	2003	Van Kerkhoven D et al.	Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams.
12461005	J. Antimicrob. Chemother.	2002	Matysiak-Budnik T et al.	In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: effect of Helicobacter pylori.
12461011	J. Antimicrob. Chemother.	2002	Ahrén IL et al.	Comparison of the antibacterial activities of ampicillin, ciprofloxacin, clarithromycin, telithromycin and quinupristin/dalfopristin against intracellular non-typeable Haemophilus influenzae.
12888589	J. Antimicrob. Chemother.	2003	Gotfried MH et al.	Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects.
12837729	J. Antimicrob. Chemother.	2003	Cynamon MH et al.	Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection.
10588313	J. Antimicrob. Chemother.	1999	Langan CE et al.	Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis.
10747833	J. Antimicrob. Chemother.	2000	Paton R et al.	Susceptibility testing of Haemophilus influenzae to clarithromycin.
10933651	J. Antimicrob. Chemother.	2000	Theron AJ et al.	Investigation of the anti-inflammatory and membrane-stabilizing potential of spiramycin in vitro.
10980165	J. Antimicrob. Chemother.	2000	Bosne-David S et al.	Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors.
11020255	J. Antimicrob. Chemother.	2000	Cirioni O et al.	Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline.
11020260	J. Antimicrob. Chemother.	2000	Alarcón T et al.	Clarithromycin resistance stability in Helicobacter pylori: influence of the MIC and type of mutation in the 23S rRNA.
11020269	J. Antimicrob. Chemother.	2000	Guyot A et al.	Clarithromycin appears to be linked with Clostridium difficile-associated diarrhoea in the elderly.
10882691	J. Antimicrob. Chemother.	2000	Yanagihara K et al.	Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation.
10702548	J. Antimicrob. Chemother.	2000	Ives TJ et al.	In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected vero cell monolayers.
10629013	J. Antimicrob. Chemother.	2000	Bui KQ et al.	In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.
15347635	J. Antimicrob. Chemother.	2004	Koga T et al.	Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
15269191	J. Antimicrob. Chemother.	2004	Tellier G et al.	Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
15140858	J. Antimicrob. Chemother.	2004	Buxbaum A et al.	Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae in Austria.
21393190	J. Antimicrob. Chemother.	2011	Inagaki T et al.	Evaluation of a rapid detection method of clarithromycin resistance genes in Mycobacterium avium complex isolates.
21406436	J. Antimicrob. Chemother.	2011	Cirioni O et al.	Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection.
19477891	J. Antimicrob. Chemother.	2009	Jespersen CM et al.	Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial.
20008044	J. Antimicrob. Chemother.	2010	De Francesco V et al.	Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits.
17329269	J. Antimicrob. Chemother.	2007	De Francesco V et al.	Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy.
16284224	J. Antimicrob. Chemother.	2006	Posteraro P et al.	Rapid detection of clarithromycin resistance in Helicobacter pylori using a PCR-based denaturing HPLC assay.
21764826	J. Antimicrob. Chemother.	2011	Oleastro M et al.	Primary antibiotic resistance of Helicobacter pylori strains isolated from Portuguese children: a prospective multicentre study over a 10 year period.
21791441	J. Antimicrob. Chemother.	2011	Tagliabue C et al.	Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.
17412724	J. Antimicrob. Chemother.	2007	Shinkai M et al.	Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin.
17846106	J. Antimicrob. Chemother.	2007	de Steenwinkel JE et al.	Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice.
17827146	J. Antimicrob. Chemother.	2007	Sasaki M et al.	Effect of plaunotol in combination with clarithromycin against clarithromycin-resistant Helicobacter pylori in vitro and in vivo.
15824090	J. Antimicrob. Chemother.	2005	Guna R et al.	In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
16303883	J. Antimicrob. Chemother.	2006	Cai S et al.	Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones.
16024590	J. Antimicrob. Chemother.	2005	Sun HK et al.	Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model.
16006447	J. Antimicrob. Chemother.	2005	Williams AC et al.	Differential effects of three antibiotics on T helper cell cytokine expression.
16549515	J. Antimicrob. Chemother.	2006	Giamarellos-Bourboulis EJ et al.	Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae.
17218449	J. Antimicrob. Chemother.	2007	Anderson R et al.	Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae.
17208955	J. Antimicrob. Chemother.	2007	Ozsoylar G et al.	Clarithromycin monotherapy-induced delirium.
18467303	J. Antimicrob. Chemother.	2008	Falagas ME et al.	Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis.
22687889	J. Antimicrob. Chemother.	2012	Cuadrado-Lavín A et al.	Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial.
22833642	J. Antimicrob. Chemother.	2012	Maurer FP et al.	Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41).